For the fourth consecutive year, outcomes for patients receiving allogeneic transplants through the Blood and Marrow Transplant Program at Roswell Park Cancer Institute (RPCI) have been shown to be significantly better than would be expected among the patient population treated. The latest report compiled by the Center for International Blood and Marrow Transplant Research (CIBMTR) identifies RPCI as one of 13 "over-performing" U.S. transplant centers.
The CIBMTR collects and annually publishes data from centers that perform allogeneic blood and marrow transplantation (BMT), which involves infusion of bone marrow or blood cells from a related or unrelated donor and is commonly used to treat many blood cancers, including acute and chronic leukemias, multiple myeloma and lymphoma. The international research organization's 2013 report analyzed related-donor and unrelated-donor transplants performed between 2009 and 2011, reflecting outcomes data for 168 U.S. centers.
Among those 168 centers, RPCI was one of 13 whose patient outcomes — specifically, the survival rate for allogeneic BMT patients one year following transplant — were above what could be expected based on case acuity, which takes into consideration factors such as a patient's age, co-morbidities, remission status and level of donor match. Just six of those 13 centers, including RPCI, were identified as "over-performing" in both the 2012 and 2013 CIBMTR reports.
"These annual assessments from the CIBMTR are a benchmark that is important for all transplant centers and patients," notes Philip McCarthy, MD, Professor of Oncology and Director of the Blood & Marrow Transplant Program. "We're proud of our consistent high performance, which means better survival for our patients, who are facing difficult diagnoses and complex, long-term treatment plans."
Source: Roswell Park Cancer Institute